Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Ovarian Neoplasms

Free Subscription 21.09.2026 2 Am J Obstet Gynecol 1 Am J Surg Pathol 1 BMC Cancer 1 Br J Cancer 1 Cancer 1 Cancer Res 4 Gynecol Oncol 1 Mol Ther Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Obstet Gynecol

1. LAZOVIC S, Chen L, Rouse KJ, Fischkoff K, et al
   Standalone Salpingectomy for Primary Ovarian Cancer Prevention: A Cost-Effectiveness Analysis.
   Am J Obstet Gynecol. 2026 Sep 18:S0002-9378(26)00499.
   PubMed         Abstract available
   
   
2. GOOTZEN TA, Norquist BM, Wilke RN, Hoppenreijs B, et al
   International Trends in Concurrent Hysterectomy at Risk-Reducing Surgery in BRCA1/2 pathogenic variant carriers: A mixed-methods study.
   Am J Obstet Gynecol. 2026 Jun 20:S0002-9378(26)00324.
   PubMed         Abstract available
   
   

   
   Am J Surg Pathol

3. DINH TA, Torrez MM, Konopka KE, Perry WR, et al
   Metastatic High-Grade Endometrioid Carcinoma to the Lung With Pilomatrix Carcinoma-Like Morphology: Potential for Misdiagnosis as Non-Small Cell Carcinoma.
   Am J Surg Pathol. 2026 Jul 28. doi: 10.1097/PAS.0000000000002591.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. QIAO ZW, Jiang Y, Wang L, Wang L, et al
   Retraction Note: LINC00852 promotes the proliferation and invasion of ovarian cancer cells by competitively binding with miR-140-3p to regulate AGTR1 expression.
   BMC Cancer. 2026;26:1092.
   PubMed        
   
   

   
   Br J Cancer

5. SJOQUIST KM, Dobrovic A, Robledo KP, Nesic K, et al
   Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.
   Br J Cancer. 2026 Jul 8. doi: 10.1038/s41416-026-03535.
   PubMed         Abstract available
   
   

   
   Cancer

6. MANNING WB, Youssef AM, Yeku OO
   IMMU-NO versus yes: Applicability of immune checkpoint inhibitors in gynecologic cancers.
   Cancer. 2026;132:e70611.
   PubMed         Abstract available
   
   

   
   Cancer Res

7. SOLOMON N, Scharff Y, Rubinstein Y, Monteran L, et al
   Stromal-Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma.
   Cancer Res. 2026 Jul 17:OF1-OF19. doi: 10.1158/0008-5472.CAN-25-2439.
   PubMed         Abstract available
   
   

   
   Gynecol Oncol

8. GRISHAM RN, Van Nieuwenhuysen E, Santin AD, D'Hondt V, et al
   Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201.
   Gynecol Oncol. 2026;213:59-67.
   PubMed         Abstract available
   
   
9. RIESE C, Yi-Tung E, Nilsson H, Salehi S, et al
   Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980-2023) with focus on younger women (0-49 years old).
   Gynecol Oncol. 2026;212:152-159.
   PubMed         Abstract available
   
   
10. HOPP EE, Enserro D, Campos S, Chitiyo V, et al
    A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor.
    Gynecol Oncol. 2026;212:98-105.
    PubMed         Abstract available
    
    
11. DE TOMMASI O, Palmieri L, Bellone S, Buza N, et al
    Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRalpha), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic sub
    Gynecol Oncol. 2026;212:72-79.
    PubMed         Abstract available
    
    

    
    Mol Ther Oncol

12. OGUNSANYA A, Alfaran F, Amadu ON, Padmanabhan A, et al
    USP15 regulates mitotic fidelity, metastatic potential, and chemotherapeutic response in ovarian cancer cells.
    Mol Ther Oncol. 2026;34:201329.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum